[go: up one dir, main page]

KR900701311A - 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 - Google Patents

재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법

Info

Publication number
KR900701311A
KR900701311A KR1019900701665A KR900701665A KR900701311A KR 900701311 A KR900701311 A KR 900701311A KR 1019900701665 A KR1019900701665 A KR 1019900701665A KR 900701665 A KR900701665 A KR 900701665A KR 900701311 A KR900701311 A KR 900701311A
Authority
KR
South Korea
Prior art keywords
interferon
recombinant human
squamous cell
cell carcinoma
intralesionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900701665A
Other languages
English (en)
Other versions
KR950011889B1 (ko
Inventor
제이. 텐너 다니엘
에이. 피츠 에드윈
에이. 스마일스 케니스
Original Assignee
스타이나 브이, 칸스타드
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타이나 브이, 칸스타드, 쉐링 코포레이션 filed Critical 스타이나 브이, 칸스타드
Publication of KR900701311A publication Critical patent/KR900701311A/ko
Application granted granted Critical
Publication of KR950011889B1 publication Critical patent/KR950011889B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 치료를 요하는 사람에게 항-편평세포 암제로서 유효한 충분량의 재조합 사람 α-2인터페론을 병소내 투여함을 특징으로 하는 사람 편평세포 암을 치료하는 방법.
  2. 제1항에 있어서, α-2인터페론이 재조합 사람 인터페론 α-2b인 방법.
  3. 제1항 또는 제2항에 있어서, 매회 주입량으로 0.1 내지 10*106국제단위의 재조합 사람 α-2 인터페론을 투여하여 치료하는 방법.
  4. 제1항, 제2항 및 제3항중 어느 한 항에 있어서, 주입용량이 1.5*106국제단위인 방법
  5. 제1항, 제2항, 제3항 및 제4항중 어느 한 항에 있어서, 주입용량이 1.5*106국제단위를 주당 3일씩 3주간 투여하는 방법.
  6. 편평세포 암의 병소내적 치료용 약제를 제조하기 위한 재조합 사람 α-2 인터페론의 용도.
  7. 편평세포 암을 병소내적으로 치료하기 위한 재조합 사람 α-2인터페론의 용도.
  8. 편평세포암을 병소내적으로 치료하는데 사용하기 위한 재조합 사람 α-2인터페론을 함유하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900701665A 1988-12-01 1989-11-29 정제된 재조합 사람 α-2 인터페론을 포함하는, 편평세포암 치료에 유용한 병소내 투여용 약제학적 조성물 Expired - Fee Related KR950011889B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27831588A 1988-12-01 1988-12-01
US278,315 1988-12-01
US88-278,315 1988-12-01
PCT/US1989/005287 WO1990006135A1 (en) 1988-12-01 1989-11-29 Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon

Publications (2)

Publication Number Publication Date
KR900701311A true KR900701311A (ko) 1990-12-01
KR950011889B1 KR950011889B1 (ko) 1995-10-12

Family

ID=23064525

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701665A Expired - Fee Related KR950011889B1 (ko) 1988-12-01 1989-11-29 정제된 재조합 사람 α-2 인터페론을 포함하는, 편평세포암 치료에 유용한 병소내 투여용 약제학적 조성물

Country Status (14)

Country Link
EP (2) EP0446279A1 (ko)
JP (1) JPH0647556B2 (ko)
KR (1) KR950011889B1 (ko)
AT (1) ATE92333T1 (ko)
AU (1) AU634511B2 (ko)
CA (1) CA2004202C (ko)
DE (1) DE68908119T2 (ko)
DK (1) DK103891D0 (ko)
ES (1) ES2058555T3 (ko)
IE (1) IE63121B1 (ko)
IL (1) IL92495A (ko)
MY (1) MY107071A (ko)
WO (1) WO1990006135A1 (ko)
ZA (1) ZA899113B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9139091A (en) * 1990-12-14 1992-07-08 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
WO1992011025A2 (en) * 1990-12-21 1992-07-09 Schering Corporation Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
ES2183977T3 (es) * 1995-10-04 2003-04-01 Schering Corp Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
US7294332B2 (en) 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
DK264787A (da) * 1986-05-27 1987-11-28 Schering Corp Anvendelse af humant alfa-interferon til fremstilling af et pharmaceutisk praeparat

Also Published As

Publication number Publication date
CA2004202A1 (en) 1990-06-01
DK103891A (da) 1991-05-31
ES2058555T3 (es) 1994-11-01
IL92495A0 (en) 1990-08-31
KR950011889B1 (ko) 1995-10-12
EP0372809B1 (en) 1993-08-04
JPH0647556B2 (ja) 1994-06-22
MY107071A (en) 1995-09-30
ZA899113B (en) 1990-08-29
EP0446279A1 (en) 1991-09-18
CA2004202C (en) 2001-02-13
JPH04500678A (ja) 1992-02-06
IE893828L (en) 1990-06-01
WO1990006135A1 (en) 1990-06-14
IE63121B1 (en) 1995-03-22
IL92495A (en) 1995-05-26
AU4802590A (en) 1990-06-26
DE68908119T2 (de) 1993-11-18
DK103891D0 (da) 1991-05-31
ATE92333T1 (de) 1993-08-15
AU634511B2 (en) 1993-02-25
EP0372809A1 (en) 1990-06-13
DE68908119D1 (de) 1993-09-09

Similar Documents

Publication Publication Date Title
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
DE69220808D1 (de) Vorrichtung zur verabreichung von heilmitteln
MY117781A (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
KR910005858A (ko) 지방산 요법
DE69737723D1 (de) Behalter zur iontophoretischen verabreichung von medikamenten mit inerten material-bestandteilen
KR910700069A (ko) Gm-csf를 사용한 백혈구 기능장애의 치료
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
ATE94763T1 (de) Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
ES2036526T3 (es) Composiciones de interferon.
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
KR900701322A (ko) 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
KR900017599A (ko) 종양 치료용 약학 조성물
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
KR900700156A (ko) 개선된 방사선 치료법
JPS56138112A (en) Suppository containing ascorbic acid or sodium ascorbate
KR920014480A (ko) 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
KR890007737A (ko) 진토작용을 하는 약제

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19981013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19981013

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000